Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12345>>>
109 Items
Title  Creator  Group name  Publishing year 
[Homologous recombination deficiency in epithelial ovarian cancers: from molecular characterization to patient journey] Quesada et al. EquipePC 2023-04
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database Mailliez et al. EquipePC 2023-03-01
Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe Hofman et al. EquipePC 2023-10
PTPN13 Participates in the Regulation of Epithelial-Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells Aptecar et al. EquipePC 2023-10-21
Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study Fabbro et al. EquipePC 2023-01
HT-smFISH: a cost-effective and flexible workflow for high-throughput single-molecule RNA imaging Safieddine et al. EquipePC 2023-01
Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer Vendrell et al. EquipePC 2023-09-16
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial Kurtz et al. EquipePC 2023-10-20
[Resistance to BRAF inhibitors: A lesson from clinical observations] Dahmani et al. EquipePC 2022 Jun-Jul
[Combining surgery and medical treatments for ovarian cancer: Is there an optimal strategy?] Thomas et al. EquipePC 2022-02
Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study Falandry et al. EquipePC 2022-03
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations Quesada et al. EquipePC 2022-02-23
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives Quesada et al. EquipePC 2022-02-21
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial Bidard et al. EquipePC 2022-11
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer Delaloge et al. EquipePC 2022-05
Sexual quality of life assessment in young women with breast cancer during adjuvant endocrine therapy and patient-reported supportive measures Bobrie et al. EquipePC 2022-04
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1 Berger et al. EquipePC 2022-03-03
Protein Phosphorylation in Cancer: Unraveling the Signaling Pathways Coopman EquipePC 2022-07-27
PeroxiHUB: A Modular Cell-Free Biosensing Platform Using H2O2 as Signal Integrator Soudier et al. EquipePC 2022-08-19
ifCNV: A novel isolation-forest-based package to detect copy-number variations from various targeted NGS datasets Cabello-Aguilar et al. EquipePC 2022-12-13
Determination of the Optimal Bacterial DNA Extraction Method to Explore the Urinary Microbiota Vendrell et al. EquipePC 2022-01-25
Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France de Calbiac et al. EquipePC 2022-09-01
Case report: Liquid biopsy, the sooner the better? Thomas et al. EquipePC 2022
The kinesin KIF1C transports APC-dependent mRNAs to cell protrusions Pichon et al. EquipePC 2021-12
Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program Bertho et al. EquipePC 2021
12345>>>
109 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés